Loading clinical trials...
Loading clinical trials...
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Trevi Therapeutics
NCT06516952 · Prurigo Nodularis
NCT06342713 · Healthy Participants, Healthy Subjects, and more
NCT06779136 · Prurigo Nodularis
NCT04204616 · Prurigo Nodularis
NCT05991323 · Prurigo Nodularis
University of Münster
Münster
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions